I don't think anyone can debate the fact that medicine is getting tougher from every angle. New business models along with the daily research and genome updates have a tendency to make things a little shaky and unpredictable. The fact that he is from Pfizer, doesn't make much difference here with the opinions as I think all would concur, just read about the new policies at the FDA and all the new uncovered information we see every day in the news.
"The more we dig into these diseases, the more difficult it gets and the more money we need to spend. It's frustrating for everybody. But nothing in science happens overnight."
There is news every day about markers being identified and properties associated. This is one of the reasons you really need leadership with some "hands on" experience with technology and this starts from the top and shuffles down. The world is a changing place today and old style leadership needs to change as well. The fact that Mr. Hammang is a neuroscientist and is speaking out about the process and not a political leader certainly sheds some light here and people like this at the top in their area that work with science and technology just tend to tell it like it is. BD
Joseph Hammang, who oversees science policy for pharmaceutical giant Pfizer, is in North Carolina this week to visit researchers at Duke University and the University of North Carolina at Chapel Hill. He is also talking to state legislators and business executives at health-care forums in Raleigh and Charlotte. Hammang, 51, is a neuroscientist who helps shape research and development at Pfizer, which, with almost $50 billion in annual revenue, is the world's largest drugmaker.
0 comments :
Post a Comment